2020

17 09, 2020

CanaQuest Medical Corp Secures Approval For Listing On The Ocmx™, An Online Investor And Financial Connection Portal

2020-09-16T23:02:08+00:00September 17th, 2020|

TORONTO – September 17, 2020 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that it has been approved to raise capital on The OCMX™, an online portal that publicizes and provides financial connections to public and privately held investment opportunities. Planned use of proceeds for CanaQuest’s raise include helping further facilitate a funding pathway for FDA drug approval, which is already underway. The OCMX™ has spent considerable time completing its due diligence on the Company and concluded that there is indeed a tremendous opportunity for Investors and Advisors. The OCMX™ noted that, “CanaQuest [...]

14 07, 2020

CanaQuest Medical Corp Files Provisional Patent For Mentanine® – Omega-3 & Pure Cannabidiol (“CBD”) Formulation Boosting Mental Health Efficacy While Minimizing CBD Dosage

2020-07-14T13:31:46+00:00July 14th, 2020|

TORONTO – July 14, 2020 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing cannabis/hemp molecules and botanical compounds, has filed a Provisional Cannabidiol/Omega-3 Patent, trade named Mentanine®, which was developed as a result of its sponsored research program at Western University, based in London, Ontario, Canada. The application of CBD alone has little effect/impact on the ability of the Central Nervous System “CNS” to help with mental health issues. Our newly developed formula will be a “life changer” for many. The scientifically developed formula went through pre-clinical studies at Western University. Results from these pre-clinical trials, addressing anxiety, depression, PTSD, and schizophrenia [...]

6 02, 2020

Canaquest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®

2020-02-06T17:16:59+00:00February 6th, 2020|

Toronto, Feb. 06, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a developer of novel health products utilizing cannabis, hemp, and botanical extracts, including algae oils, today announced it has applied to Health Canada for approval to produce, sell and export Mentabinol® (THC based, all-natural formulation) under the Cannabis Act. Approval of the filed application is anticipated in March 2020 and will enable CanaQuest and its Licensed Processor partners, who are capable of formulating, processing, packaging and distribution throughout Canada to initiate sales and global exports 30 days after approval. CanaQuest was awarded a Cannabis Sales/Purchase, Import/Export license from Health Canada through its wholly owned subsidiary ADC BioMedical [...]